207 related articles for article (PubMed ID: 17130941)
21. Cost-effectiveness of rotavirus vaccination in Albania.
Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
[TBL] [Abstract][Full Text] [Related]
22. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China.
Liu N; Yen C; Fang ZY; Tate JE; Jiang B; Parashar UD; Zeng G; Duan ZJ
Vaccine; 2012 Nov; 30(48):6940-5. PubMed ID: 22705174
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection.
Yamin D; Atkins KE; Remy V; Galvani AP
Value Health; 2016; 19(6):811-819. PubMed ID: 27712709
[TBL] [Abstract][Full Text] [Related]
24. An economic analysis of rotavirus vaccination in Italy.
Giammanco MD; Coniglio MA; Pignato S; Giammanco G
Vaccine; 2009 Jun; 27(29):3904-11. PubMed ID: 19446934
[TBL] [Abstract][Full Text] [Related]
25. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.
Milne RJ; Grimwood K
Value Health; 2009 Sep; 12(6):888-98. PubMed ID: 19490550
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.
Standaert B; Parez N; Tehard B; Colin X; Detournay B
Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820
[TBL] [Abstract][Full Text] [Related]
27. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.
Itzler R; O'Brien MA; Yamabe K; Abe M; Dhankhar P
J Med Econ; 2013 Oct; 16(10):1216-27. PubMed ID: 23919721
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of rotavirus vaccination in Turkey.
Koksal T; Akelma AZ; Koksal AO; Kutukoglu I; Ozdemir O; Yuksel CN; Bozkaya D; Catal F; Sari S
J Microbiol Immunol Infect; 2017 Oct; 50(5):693-699. PubMed ID: 27107612
[TBL] [Abstract][Full Text] [Related]
30. Impact and cost-effectiveness of rotavirus vaccination in Bangladesh.
Pecenka C; Parashar U; Tate JE; Khan JAM; Groman D; Chacko S; Shamsuzzaman M; Clark A; Atherly D
Vaccine; 2017 Jul; 35(32):3982-3987. PubMed ID: 28623028
[TBL] [Abstract][Full Text] [Related]
31. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
[TBL] [Abstract][Full Text] [Related]
32. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Pakistan.
Rheingans R; Anderson JD; Bagamian KH; Laytner LA; Pecenka CJ; Gilani SSA; Ahmed M
Vaccine; 2018 Dec; 36(51):7780-7789. PubMed ID: 30007826
[TBL] [Abstract][Full Text] [Related]
33. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of rotavirus vaccination in Armenia.
Jit M; Yuzbashyan R; Sahakyan G; Avagyan T; Mosina L
Vaccine; 2011 Nov; 29(48):9104-11. PubMed ID: 21945959
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
Abbott C; Tiede B; Armah G; Mahmoud A
Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
[TBL] [Abstract][Full Text] [Related]
38. Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis.
Rose J; Homa L; Meropol SB; Debanne SM; Bielefeld R; Hoyen C; Singer ME
PLoS One; 2017; 12(11):e0187446. PubMed ID: 29099848
[TBL] [Abstract][Full Text] [Related]
39. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
Podewils LJ; Antil L; Hummelman E; Bresee J; Parashar UD; Rheingans R
J Infect Dis; 2005 Sep; 192 Suppl 1():S133-45. PubMed ID: 16088797
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective.
Smith ER; Rowlinson EE; Iniguez V; Etienne KA; Rivera R; Mamani N; Rheingans R; Patzi M; Halkyer P; Leon JS
Vaccine; 2011 Sep; 29(38):6704-11. PubMed ID: 21624421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
